RYTM

Rhythm Pharmaceuticals develops treatments for rare genetic disorders that cause severe obesity and other metabolic problems. The company's main product is a medication called IMCIVREE, which is approved to treat several rare conditions where genetic mutations prevent the body from properly signaling that it is full. Rhythm is also testing other experimental medications in clinical trials to treat additional rare obesity-related conditions caused by genetic defects. The company is based in Boston and was founded in 2008.